

LISTING OF CLAIMS

1. (currently amended) A neutralizing bispecific fusion protein capable of binding to two sites on gp120, comprising a first binding domain capable of binding which binds to an inducing site on gp120, thereby exposing an induced epitope of gp120; a second binding domain capable of forming which forms a neutralizing complex with the induced epitope of gp120; and a linker connecting the first domain to the second domain, wherein the first binding domain is sCD4, and the second binding domain is SCFv(17b) and wherein the second domain is encoded by an amino acid sequence comprising at least 90% sequence identity to residues 244 through 502 of SEQ ID NO: 3.

2-22. (canceled)

23. (previously presented) A protein according to claim 1, wherein the induced epitope comprises at least one coreceptor binding determinant of gp120.

24. (previously presented) A protein according to claim 1, wherein the inducing site is a gp120 CD4 binding site.

25. (currently amended) A protein according to claim 1, wherein the SCFv(17b) is capable of binding second binding domain binds to at least one coreceptor binding determinant of gp120.

26. (original) A protein according to claim 1, wherein the linker maintains the second binding domain in binding proximity to the induced epitope when the first binding domain is bound to the inducing site.

27. (original) A protein according to claim 26, wherein the linker is substantially flexible.

28. (original) A protein according to claim 26, wherein the linker is 15-100 angstroms (\AA) long.

29. (original) A protein according to claim 26, wherein the linker is 10-100 amino acid residues in length.

30. (original) A protein according to claim 26, wherein the linker comprises at least one occurrence of an amino acid sequence as represented by SEQ ID NO: 1.

31. (original) A protein according to claim 1, wherein the linker comprises at least one occurrence of an amino acid sequence represented by SEQ ID NO: 1.

32. (original) A protein according to claim 31, wherein the linker comprises an amino acid sequence represented by SEQ ID NO: 2.

33. (previously amended) The protein according to claim 1, wherein the linker is of a length sufficient to maintain the SCFv(17b) in binding proximity to an SCFv(17b) epitope when sCD4 is bound to gp120.

34. – 36. (canceled)

37. (previously amended) The protein of claim 1, wherein the protein is encoded by a nucleic acid molecule having a sequence as set forth in SEQ ID NO: 4.

38. - 47. (canceled)

48. (previously presented) A composition comprising the protein according to claim 1.

49. - 51. (canceled)

52. (previously amended) A kit for treatment and/or prevention of HIV infection, comprising the pharmaceutical composition of claim 49.

53. (original) The kit of claim 52, further comprising instructions.

54. (original) The kit of claim 53, wherein the instructions include directions for administering at least one dose of the neutralizing bispecific fusion protein to a subject in need of such treatment.

55. (canceled)

56. (new) The protein according to claim 1, wherein the second domain is encoded by an amino acid sequence comprising at least 95% sequence identity to residues 244 through 502 of SEQ ID NO: 3.

57. (new) The protein according to claim 56, wherein the second domain is encoded by an amino acid sequence comprising at least 97% sequence identity to residues 244 through 502 of SEQ ID NO: 3.

58. (new) The protein according to claim 57, wherein the second domain is encoded by an amino acid sequence comprising at least 98% sequence identity to residues 244 through 502 of SEQ ID NO: 3.

59. (new) The protein according to claim 58, wherein the second domain is encoded by an amino acid sequence comprising at least 99% sequence identity to residues 244 through 502 of SEQ ID NO: 3.

60. (new) The protein according to claim 1, having the amino acid sequence as set forth in SEQ ID NO: 3.